BAGNEUX, France--(BUSINESS WIRE)--Regulatory News:
Genomic Vision (Paris:GV) (FR0011799907 – GV / PEA-PME eligible), a molecular diagnostics company specialized in the development of diagnostic tests for genetic diseases and cancers based on molecular combing, today publishes its financial calendar for 2016. This preliminary agenda may be modified.
| Event | Date* | ||
| 2015 Full-Year Results | Tuesday, March 22, 2016 | ||
| Q1 2016 Revenue | Tuesday, May 10, 2016 | ||
| Shareholders’ Meeting | Thursday, June 23, 2016 | ||
| 2016 Half-Year Results | Tuesday , July 26, 2016 | ||
| Q3 2016 Revenue | Friday, October 28, 2016 |
* Press releases are distributed before the financial markets open.
●●●
ABOUT GENOMIC VISION
Founded in 2004, Genomic Vision is a
molecular diagnostics company specialized in the development of
diagnostic tests for genetic diseases and cancers based on molecular
combing. Using this innovative technology that allows the direct
visualization of individual DNA molecules, Genomic Vision detects
quantitative and qualitative variations in the genome that are at the
origin of numerous serious pathologies. The Company is developing a
solid portfolio of tests that notably target breast cancer and cancer of
the colon. Since 2013, the Company has marketed the CombHeliX FSHD test
for identifying a myopathy that is difficult to detect,
Facio-scapulo-humeral dystrophy (FSHD), in the United States thanks to a
strategic alliance with Quest Diagnostics, the American leader in
diagnostic laboratory tests, and in France. Genomic Vision has been
listed on Compartment C of Euronext Paris since April 2014.
ABOUT MOLECULAR COMBING
DNA molecular combing technology
considerably improves the structural and functional analysis of DNA
molecules. DNA fibers are stretched out on glass slides, as if “combed”,
and uniformly aligned over the whole surface. It is then possible to
identify genetic anomalies by locating genes or specific sequences in a
patient’s genome using genetic markers, an approach developed by Genomic
Vision and patented under the name Genomic Morse Code. This exploration
of the entire genome at high resolution via a simple analysis enables
the direct visualization of genetic anomalies that are undetectable by
other technologies.
For further information, please go to www.genomicvision.com
Member of CAC® Mid & Small, CAC® All-Tradable and EnterNext© PEA-PME 150 indexes
